2. Academic Validation
  3. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

  • Cancer Cell. 2019 Dec 9;36(6):660-673.e11. doi: 10.1016/j.ccell.2019.11.001.
Andrei V Krivtsov 1,  Kathryn Evans 2,  Jayant Y Gadrey 1,  Benjamin K Eschle 1,  Charlie Hatton 1,  Hannah J Uckelmann 1,  Kenneth N Ross 1,  Florian Perner 1,  Sarah N Olsen 1,  Tara Pritchard 2,  Lisa McDermott 2,  Connor D Jones 2,  Duohui Jing 2,  Ali Braytee 3,  Diego Chacon 3,  Eric Earley 4,  Brian M McKeever 5,  David Claremon 6,  Andrew J Gifford 7,  Heather J Lee 8,  Beverly A Teicher 9,  John E Pimanda 10,  Dominik Beck 3,  Jennifer A Perry 1,  Malcolm A Smith 9,  Gerard M McGeehan 11,  Richard B Lock 2,  Scott A Armstrong 12
Affiliations

Affiliations

  • 1 Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA.
  • 2 Children's Cancer Institute, School of Women's and Children's Health, UNSW, Sydney 2052, Australia.
  • 3 Lowy Cancer Research Centre and the Prince of Wales Clinical School, UNSW, Sydney 2052, Australia; Centre for Health Technologies and the School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia.
  • 4 RTI International, Research Triangle Park, NC 27709, USA.
  • 5 Brian Michael McKeever, LLC, Lake Ronkonkoma, NY 11779, USA.
  • 6 CGM Pharma, LLC, Fort Washington, PA 19034, USA.
  • 7 Children's Cancer Institute, School of Women's and Children's Health, UNSW, Sydney 2052, Australia; Department of Anatomical Pathology, Prince of Wales Hospital, Sydney, NSW 2031, Australia.
  • 8 School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW 2308, Australia.
  • 9 National Cancer Institute, Bethesda, MD 20892, USA.
  • 10 Lowy Cancer Research Centre and the Prince of Wales Clinical School, UNSW, Sydney 2052, Australia; Department of Haematology, Prince of Wales Hospital, Sydney, NSW 2210, Australia.
  • 11 Syndax Pharmaceuticals, Waltham, MA 02451, USA.
  • 12 Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA. Electronic address: scott_armstrong@dfci.harvard.edu.
PMID: 31821784 DOI: 10.1016/j.ccell.2019.11.001
Abstract

Inhibition of the Menin (MEN1) and MLL (MLL1, KMT2A) interaction is a potential therapeutic strategy for MLL-rearranged (MLL-r) leukemia. Structure-based design yielded the potent, highly selective, and orally bioavailable small-molecule inhibitor VTP50469. Cell lines carrying MLL rearrangements were selectively responsive to VTP50469. VTP50469 displaced Menin from protein complexes and inhibited chromatin occupancy of MLL at select genes. Loss of MLL binding led to changes in gene expression, differentiation, and Apoptosis. Patient-derived xenograft (PDX) models derived from patients with either MLL-r acute myeloid leukemia or MLL-r acute lymphoblastic leukemia (ALL) showed dramatic reductions of leukemia burden when treated with VTP50469. Multiple mice engrafted with MLL-r ALL remained disease free for more than 1 year after treatment. These data support rapid translation of this approach to clinical trials.

Keywords

DOT1L; MLL fusion; Menin inhibitor; acute myeloid leukemia (AML); chromatin remodeling; infant B cell acute lymphoblastic leukemia (B-ALL); leukemia.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z